Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04910750
Other study ID # ERC.0003405
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 5, 2021
Est. completion date April 21, 2023

Study information

Verified date November 2022
Source Swiss Tropical & Public Health Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

By introducing pulse oximetry, with or without clinical decision support algorithms, to primary care facilities in India, Kenya, Senegal and Tanzania, the Tools for Integrated Management of Childhood Illness (TIMCI) project aims to contribute to reducing morbidity and mortality for sick children under-five while supporting the rational and efficient use of diagnostics and medicines by healthcare providers. The multi-country, multi-method evaluation aims to generate evidence on the health and quality of care impact, operational priorities, cost and cost-effectiveness of introducing these tools to facilitate national and international decision-making on scale-up.


Description:

This registry entry describes the pragmatic cluster randomised controlled trials (RCTs) conducted in India and Tanzania. In Kenya and Senegal, quasi-experimental pre-post studies are conducted (NCT05065320). These studies evaluating health, clinical and quality of care impact are complemented by embedded multi-method studies in all countries, including modified Service Provision Assessments, facility-based process mapping and time-flow studies, in-depth interviews (IDIs) with caregivers and healthcare providers, online key stakeholder surveys, routine data review, and an economic evaluation. We enrol sick children 0 to 59 months of age attending government primary care facilities a pragmatic parallel group, superiority cluster randomised controlled trial (RCT). Primary care facilities randomly are allocated (1:1) in India to pulse oximetry or control, and (1:1:1) in Tanzania to pulse oximetry plus CDSA, pulse oximetry, or control. Interventions are implemented with a package of training on the use of devices and refresher IMCI, supportive supervision, operational support and community engagement. IMCI refresher training is provided to all arms. Providers at intervention facilities are provided with handheld, UNICEF-approved, pulse oximeters along with guidance and training in line with government-approved criteria. In Tanzania, healthcare providers are advised to measure oxygen saturation (SpO2) on all children under 2 months of age, all children 2 to 59 months of age with cough or difficulty breathing or with signs of moderate or severe disease based on Integrated Management of Childhood Illness (IMCI); in India, healthcare providers are advised to measure oxygen saturation for all sick children. Providers are advised to urgently refer children with SpO2 <90%. The tablet-based CDSA provides step-by-step support to healthcare providers through consultations, providing national guideline-based recommendations on assessment, diagnosis and treatment based tailored to the individual child based on information entered by the provider. Following training, providers are advised to use CDSA for all consultations with sick children under 5 years of age. Sociodemographic and clinical data are collected from caregivers and records of enrolled sick children at study facilities, with phone follow-up on Day 7 and Day 28. Two primary outcomes are assessed for the RCT: severe complications by Day 7 (mortality and 'secondary hospitalisations' i.e. delayed ≥24 hours from the Day 0 consultation, or without referral); and 'primary' hospitalisations (within 24hrs the Day 0 consultation and with referral). Secondary outcomes for the RCT, relating to hypoxaemia, referral, antimicrobial prescription, follow-up, health status, are further detailed in the attached full protocol and statistical analysis plan available. The RCT sample size was estimated based on planned enrolment over 12 months and ability to detect a ≥30% decrease in severe complications (from 1.1%22) and ≥30% increase in primary hospitalisations (from 1.5%, based on facility estimates) for each arm compared to control with 80% power, 0.05 alpha per arm, and intra-cluster correlation coefficient (ICC) of 0.00147. Anticipated feasible enrolment rates were based on DHIS2 and facility data. In Tanzania, 22 clusters per arm, each recruiting an average of 1680 children, were estimated to be needed (total 110,880). In India, 40 clusters per arm, each recruiting an average of 510 children, were estimated to be needed (total 40,800). Study approval has been granted by all relevant institutional review boards, national and WHO ethical review committees. Findings will be shared with communities, healthcare providers, Ministries of Health and other local, national and international stakeholders to facilitate evidence-based decision-making on scale-up.


Recruitment information / eligibility

Status Completed
Enrollment 167517
Est. completion date April 21, 2023
Est. primary completion date April 21, 2023
Accepts healthy volunteers No
Gender All
Age group 1 Day to 5 Years
Eligibility Individual child inclusion: - Children 0 - 59 months for whom caregivers provide consent - Consulting for an illness, or reported to be unwell when attending for a routine visit (e.g. vaccination, growth or chronic disease monitoring) Individual child exclusion: - Children in the immediate post-natal period or first day of life - Attending for a consultation related to trauma only (including new and follow-up presentations for burns, injuries, wounds) - Admitted within an inpatient part of the facility (including neonates delivered at the facility admitted with their mother) - Enrolled in the study within the preceding 28 days at any study facility

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Pulse oximetry
Pulse oximeters are a non-invasive, accurate and easy to use method of evaluating blood oxygen saturation
Clinical Decision Support Algorithm
Tablet-based clinical decision support algorithms, based on guidelines for the assessment and management of sick children under 5 years of age at primary care

Locations

Country Name City State
Tanzania Bukemba Kaliua
Tanzania Igombe 60 Kaliua
Tanzania Imalamihayo Kaliua
Tanzania Kazaroho Kaliua
Tanzania Seleli Kaliua
Tanzania Ulyankulu Kaliua
Tanzania Uyowa Kaliua
Tanzania Igalagalilo Sengerema
Tanzania Kagunga Sengerema
Tanzania Kamanga Sengerema
Tanzania Kasungamile Sengerema
Tanzania Mulaga Sengerema
Tanzania Mwabaluhi Sengerema
Tanzania Nyamazugo Sengerema
Tanzania Sengerema Sengerema
Tanzania Sengerema Secondary Sengerema
Tanzania Duga Tanga
Tanzania Kange Tanga
Tanzania Kisosora Tanga
Tanzania Kwanjekanyota Tanga
Tanzania Machui Tanga
Tanzania Mafuriko Tanga
Tanzania Magaoni Tanga
Tanzania Mpirani Tanga
Tanzania Mwakidila Tanga
Tanzania Ngamiani Tanga
Tanzania Nguvumali Tanga

Sponsors (5)

Lead Sponsor Collaborator
Swiss Tropical & Public Health Institute Ifakara Health Institute, King George's Medical University, PATH, University of Waterloo

Country where clinical trial is conducted

Tanzania, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of children with a severe complication (death or secondary hospitalisation) by Day 7 Secondary hospitalisation refers to any delayed hospitalisation (occurring at any point greater than 24 hours after Day 0 consultation) and any hospitalisation occurring without referral. The denominator is all enrolled children. From enrolment up to 7 days after
Primary Proportion of children admitted to hospital within 24 hours of the Day 0 primary care consultation and as a result of a referral This is used as a proxy for 'appropriate referral' of children, as those with severe disease should generally be admitted to hospital. The denominator for this outcomes is all children enrolled in the study, rather than only referred children. This is because the proportion of referred children that are admitted may be high in routine care, in the context of an inappropriately low referral rate. The aim of the intervention is therefore to increase the overall referral rate of children with severe disease. Hospital admission is chosen as the proxy of severe disease rather than using primary care classification of severe disease, as there are inadequacies in the classification of severe disease in routine practice.
A child will be considered admitted to hospital 24hrs of Day0 consultation if the date of hospitalization is the same as Day0 date or is one day after Day0 date.
From enrolment up to 1 day after
Secondary Proportion of children with severe complication (death or secondary hospitalisation) by Day 28 Secondary hospitalisation refers to any delayed hospitalisation (occurring at any point greater than 24 hours after Day 0 consultation) and any hospitalisation occurring without referral. The denominator is all enrolled children. From enrolment up to 28 days after
Secondary Proportion of children cured (defined as caregiver reported recovery from illness) by Day 7 The denominator will be all children recruited. A window of +3 days from Day 7 is considered. From enrolment up to 10 days after
Secondary Proportion of children referred by a primary care healthcare provider to a higher level of care (either to a hospital or to an inpatient part of a larger primary healthcare facility) at Day 0 consultation The denominator will be all children recruited. Only urgent referrals will be considered. At time of enrolment
Secondary Proportion of children who completed referral, as reported at day 7 follow-up Only urgent referrals will be considered. A referral will be considered completed if a child attended a hospital, whether was admitted or not. A window of +3 days from Day 7 is considered. From enrolment up to 10 days after
Secondary Proportion of children with non-severe disease referred to a higher level of care on Day 0 Only urgent referrals will be considered. Only urgent referrals will be considered. At time of enrolment
Secondary Average length of stay (in days) of children admitted to hospital If a child is hospitalised twice, the first hospitalization will be used and second hospitalizations will be reported separately. The denominator will be all hospitalised children. This is not a time-to-event measure, as it will be analysed as a continuous variable. From hospital admission to discharge
Secondary Proportion of children prescribed an antibiotic at Day 0 Only antibacterials for systemic use will be taken into account for the definition of antibiotics. All children recruited will be counted in the denominator. At time of enrolment
Secondary Proportion of children prescribed a diagnosis-appropriate antibiotic Appropriateness of antibiotic prescription in relation to diagnosis will be evaluated as:
diagnosis for which a systemic antibiotic was indicated and a systemic antibiotic was prescribed
diagnosis for which a systemic antibiotic was not indicated and systemic antibiotic was prescribed
first-line (or second-line) antibiotics were prescribed according to recommendations for IMCI diagnoses for which specific antibiotic(s)are indicated
Diagnoses will be classified according to whether systemic antibiotics are indicated, based on IMCI and other relevant national guidelines as used for the CDSA.
At time of enrolment
Secondary Proportion of febrile children tested for malaria at Day 0 A child will be considered to be febrile if history of fever was reported by the caregiver before the consultation or temperature was recorded to be above or equal 37.5 C°. Only febrile children will be counted in the denominator. At time of enrolment
Secondary Proportion of malaria positive children prescribed an antimalarial Only children with a positive malaria test result will be counted in the denominator. At time of enrolment
Secondary Proportion of malaria negative children prescribed an antimalarial Only children with a negative malaria test result will be counted in the denominator. At time of enrolment
Secondary Proportion of untested children prescribed an antimalarial Only children untested for malaria will be counted in the denominator. At time of enrolment
Secondary Proportion of children with severe, moderate and mild hypoxaemia, adjusted for sites at high altitude The following SpO2 values ranges will be used: SpO2 < 90%, 90% = SpO2 < 92% and 92% = SpO2 < 94%. All children recruited will be in the denominator. At time of enrolment
Secondary Proportion of children with hypoxaemia (according to differing cut-offs) with severe complication The following SpO2 values ranges will be used: SpO2 < 90%, 90% = SpO2 < 92% and 92% = SpO2 < 94%, spurious values and missing values. Each SpO2 group will be the denominator of each proportion. At time of enrolment
Secondary Proportion of children with severe hypoxaemia not meeting any other clinical criteria for severe disease Country's specific cut-off for severe hypoxaemia will be used. All children recruited will be in the denominator. At time of enrolment
Secondary Proportion of children referred with hypoxaemia who receive oxygen at hospital All children recruited will be in the denominator. Referral and hypoxaemia are assessed at Day0 consultation. Oxygen use at hospital is only available for hospitalised children from hospital records. At the time of enrolment hypoxaemia is measured and referral advise might be issued. Whether the child received oxygen or not at hospital is evaluated based on hospital registry and it refers to oxygen given at arrival to hospital. The specified time frame takes into account that the outcome is evaluated considering information recorded at different time points. At time of enrolment and at time of hospitalization
Secondary Proportion of children attending scheduled follow-up at the same facility by Day 7 All children recruited will be in the denominator. From enrolment up to 7 days after
Secondary Proportion of children presenting for unscheduled follow-up to any health facility by Day 7 All children recruited will be in the denominator. From enrolment up to 7 days after
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04244474 - Effect of Vitamin D Supplementation on Improvement of Pneumonic Children Phase 1/Phase 2
Completed NCT05815264 - Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above Phase 1
Recruiting NCT04589936 - Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care N/A
Completed NCT02905383 - The Effect of Exercise on Physical Function and Health in Older People After Discharge From Hospital N/A
Completed NCT06210737 - A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months,7 Months-5 Years Phase 4
Terminated NCT03944551 - Bubble Continuous Positive Airway Pressure for Children With Severe Pneumonia in Mali, Africa N/A
Terminated NCT04660084 - Impact of Molecular Testing on Improved Diagnosis, Treatment and Management of CAP N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Withdrawn NCT05702788 - Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19) Phase 2
Not yet recruiting NCT04171674 - Pharmacokinetics of High-dose Ceftobiprole in Community-acquired Pneumonia Under Mechanical Ventilation. N/A
Active, not recruiting NCT03140163 - Screening for Pneumonia: A Comparison of Ultra Low Dose Chest CT [ULD-CT] and Conventional Chest Radiography [CXR] N/A
Completed NCT02864420 - Hospitalization at Home: The Acute Care Home Hospital Program for Adults N/A
Completed NCT02638649 - Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath
Recruiting NCT02515565 - Physiotherapy in Patients Hospitalized Due to Pneumonia. N/A
Completed NCT02105298 - Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study) N/A
Completed NCT01399723 - Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia Phase 3
Completed NCT01416519 - Physiotherapy Technique Decreases Respiratory Complications After Cardiac Operation N/A
Completed NCT01446926 - Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants Phase 1
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Terminated NCT02358642 - Drug to Prevent Pneumonia in the Tube Fed Phase 4